Targeting CXCR4 with R54 reverts CXCL12-induced cancer cell growth in presence of CDDP/PTX, particularly in OVCAR8 and IGROV1 treated with PTX potentiating the effect of chemotherapeutic agents (Fig 5A and S6A Fig). Here, CXCR4 is linked to cancer.